KR20220057558A - 항-cd73 항체 - Google Patents

항-cd73 항체 Download PDF

Info

Publication number
KR20220057558A
KR20220057558A KR1020227010511A KR20227010511A KR20220057558A KR 20220057558 A KR20220057558 A KR 20220057558A KR 1020227010511 A KR1020227010511 A KR 1020227010511A KR 20227010511 A KR20227010511 A KR 20227010511A KR 20220057558 A KR20220057558 A KR 20220057558A
Authority
KR
South Korea
Prior art keywords
antibody
amino acid
seq
acid sequence
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227010511A
Other languages
English (en)
Korean (ko)
Inventor
마이클 몬라드 그란달
토르벤 젯팅
요한 란토
야누스 슈 야콥센
랜디 웨스트 한센
카밀라 프뢰리히
Original Assignee
심포젠 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 심포젠 에이/에스 filed Critical 심포젠 에이/에스
Publication of KR20220057558A publication Critical patent/KR20220057558A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03005—5'-Nucleotidase (3.1.3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227010511A 2019-09-06 2020-09-04 항-cd73 항체 Pending KR20220057558A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962896908P 2019-09-06 2019-09-06
US62/896,908 2019-09-06
PCT/EP2020/074804 WO2021044005A1 (en) 2019-09-06 2020-09-04 Anti-cd73 antibodies

Publications (1)

Publication Number Publication Date
KR20220057558A true KR20220057558A (ko) 2022-05-09

Family

ID=72517218

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227010511A Pending KR20220057558A (ko) 2019-09-06 2020-09-04 항-cd73 항체

Country Status (18)

Country Link
US (2) US11634500B2 (cg-RX-API-DMAC7.html)
EP (1) EP4025605A1 (cg-RX-API-DMAC7.html)
JP (1) JP7662617B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220057558A (cg-RX-API-DMAC7.html)
CN (1) CN115023439B (cg-RX-API-DMAC7.html)
AU (1) AU2020342778A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003956A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153213A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002093A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022002622A2 (cg-RX-API-DMAC7.html)
IL (1) IL291068A (cg-RX-API-DMAC7.html)
MX (1) MX2022002682A (cg-RX-API-DMAC7.html)
MY (1) MY207784A (cg-RX-API-DMAC7.html)
PE (1) PE20220708A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550509A1 (cg-RX-API-DMAC7.html)
TW (1) TWI859319B (cg-RX-API-DMAC7.html)
UA (1) UA130408C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021044005A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025135233A1 (ko) * 2023-12-21 2025-06-26 ㈜지아이이노베이션 Cd73에 특이적으로 결합하는 항체 및 이의 용도

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220317A (es) 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
EP4084870A1 (en) 2020-01-03 2022-11-09 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
CN115734972A (zh) * 2020-06-22 2023-03-03 信达生物制药(苏州)有限公司 抗cd73抗体及其用途
GB202105110D0 (en) * 2021-04-09 2021-05-26 Cancer Research Tech Ltd Anti-CD73 antibodies
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN117304316A (zh) * 2022-06-22 2023-12-29 复旦大学 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN116178546B (zh) * 2022-10-13 2024-06-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US256055A (en) 1882-04-04 Compound engine
US323997A (en) 1885-08-11 Machine-gun
US338841A (en) 1886-03-30 herden
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
IL146005A0 (en) 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
WO2001080884A1 (en) 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
WO2006113181A2 (en) 2005-04-08 2006-10-26 University Of Florida Research Foundation, Inc. Stem-like cells in bone sarcomas
EP1883424A2 (en) 2005-05-18 2008-02-06 Biogen Idec Inc. Methods for treating fibrotic conditions
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8975081B2 (en) 2007-10-24 2015-03-10 Faron Pharmaceuticals Oy Biomarker for monitoring development of diseases and assessing the efficacy of therapies
EP2593595B1 (en) * 2010-07-16 2020-03-11 Avantgen, Inc. Novel peptides and uses thereof
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
WO2015136472A1 (en) * 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
EP3789403A1 (en) 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cd73に対する抗体およびその使用
WO2016196912A1 (en) 2015-06-03 2016-12-08 Dana-Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
PL3368572T5 (pl) * 2015-10-02 2026-07-20 Les Laboratoires Servier Przeciwciała anty-PD-1 oraz kompozycje
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
CA3007646A1 (en) 2015-12-09 2017-06-15 Bioatla, Llc Humanized anti-cd73 antibodies
EP3436829A1 (en) 2016-03-30 2019-02-06 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
EP3481869A4 (en) 2016-07-11 2020-02-26 Corvus Pharmaceuticals, Inc. ANTI-CD73 ANTIBODIES
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
US11390676B2 (en) * 2016-10-13 2022-07-19 Symphogen A/S Anti-LAG-3 antibodies and compositions
CA3045376C (en) * 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
WO2018187512A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
CN119431579A (zh) 2018-03-09 2025-02-14 艾吉纳斯公司 抗cd73抗体及其使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025135233A1 (ko) * 2023-12-21 2025-06-26 ㈜지아이이노베이션 Cd73에 특이적으로 결합하는 항체 및 이의 용도

Also Published As

Publication number Publication date
IL291068A (en) 2022-05-01
US20210070876A1 (en) 2021-03-11
AU2020342778A1 (en) 2022-03-31
NZ785824A (en) 2025-10-31
CA3153213A1 (en) 2021-03-11
CN115023439B (zh) 2026-04-03
JP2022547081A (ja) 2022-11-10
BR112022003956A2 (pt) 2022-05-24
JP7662617B2 (ja) 2025-04-15
US11634500B2 (en) 2023-04-25
CL2024002093A1 (es) 2024-12-27
WO2021044005A1 (en) 2021-03-11
CN115023439A (zh) 2022-09-06
MX2022002682A (es) 2022-04-07
PE20220708A1 (es) 2022-05-04
EP4025605A1 (en) 2022-07-13
TWI859319B (zh) 2024-10-21
MY207784A (en) 2025-03-18
PH12022550509A1 (en) 2023-03-20
UA130408C2 (uk) 2026-02-11
US20230227573A1 (en) 2023-07-20
CO2022002622A2 (es) 2022-04-08
TW202122423A (zh) 2021-06-16

Similar Documents

Publication Publication Date Title
JP7662617B2 (ja) 抗cd73抗体
JP7488323B2 (ja) 抗lag-3抗体および組成物
JP6875385B2 (ja) 抗pd−1抗体および組成物
TWI752950B (zh) 抗tim-3抗體及組成物
AU2021225490B2 (en) Anti-AXL antibodies and compositions
US20210284734A1 (en) Anti-pd-1 antibodies and compositions
CA3039140C (en) Anti-lag-3 antibodies and compositions
HK40076937A (en) Anti-cd73 antibodies
CA3000564C (en) Anti-pd-1 antibodies and compositions
HK40085294A (en) Anti-pd-1 antibodies and compositions
EA046220B1 (ru) Анти-lag-3 антитела и их композиции
HK1256846B (en) Anti-pd-1 antibodies and compositions
HK1256846A1 (en) Anti-pd-1 antibodies and compositions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000